Vandateroside I

Vandateroside I

SCHEMBL15022617

O=C(C[C@](O)(Cc1ccc(O)cc1)C(=O)O)OCc1ccc(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TYR P14679 2/20 0.60
▸ SLC5A1 P13866 4/20 0.47
▸ HPGD P15428 2/20 0.47
▸ HSD17B10 Q99714 2/20 0.47
▸ SLC5A2 P31639 2/20 0.47
▸ SLC28A3 Q9HAS3 2/20 0.47
▸ KDM4E B2RXH2 2/20 0.47
▸ MAPT P10636 2/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ THRB P10828 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ SLC28A2 O43868 1/20 0.47
▸ EPHX2 P34913 1/20 0.47
▸ NPC1 O15118 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ AKR1B1 P15121 1/20 0.46
▸ DPP4 P27487 1/20 0.46
▸ POLB P06746 1/20 0.45
▸ GAA P10253 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Vandateroside I SCHEMBL15033271 1.00 TYR (0.60) TYRSLC5A1HPGDHSD17B10SLC5A2
Vandateroside Ii SCHEMBL15022381 0.93 TYR (0.58) TYRSLC5A1HPGDHSD17B10SLC5A2
Vandateroside Ii SCHEMBL15033269 0.93 TYR (0.58) TYRSLC5A1HPGDHSD17B10SLC5A2
SCHEMBL29941871 0.92 TYR (0.57) TYRSLC5A1HPGDHSD17B10KDM4E
SCHEMBL29392767 0.89 TYR (0.54) TYRSLC5A1HPGDHSD17B10KDM4E
SCHEMBL28049269 0.87 TYR (0.56) TYRSLC5A1HPGDHSD17B10KDM4E
SCHEMBL28755274 0.86 TYR (0.51) TYRSLC5A1NPC1RAB9AAKR1B1
SCHEMBL30047083 0.86 TYR (0.50) TYRSLC5A1SLC5A2NPC1RAB9A
SCHEMBL29392493 0.85 TYR (0.52) TYRSLC5A1HPGDHSD17B10KDM4E
Parishin SCHEMBL29432429 0.82 TYR (0.51) TYRSLC5A1HPGDHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2556080-B1 COSMETIC COMPOSITION GUERLAIN (FR) 2015-06-03 — — EP claimed
US-9012414-B2 Cosmetic composition GUERLAIN (FR) 2015-04-21 — — US claimed
US-20130157968-A1 COSMETIC COMPOSITION CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-06-20 — — US claimed
EP-2556080-B1 COSMETIC COMPOSITION GUERLAIN (FR) 2015-06-03 — — EP disclosed
US-9012414-B2 Cosmetic composition GUERLAIN (FR) 2015-04-21 — — US disclosed
US-20130157968-A1 COSMETIC COMPOSITION CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-06-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130157968-A1 COSMETIC COMPOSITION H1-0, H1-2, H1-3 TYR 15/4885SLC5A1 1067/4885HPGD 1513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback